Current state of biomarker development for clinical application in epithelial ovarian cancer.

Nearly 200,000 women will undergo surgery on an annual basis for the diagnosis of a pelvic mass, and anywhere from 13-21% of these women will be diagnosed with epithelial ovarian cancer( 35 ; 36 ). Women whose malignancy can be predicted preoperatively so that their surgery can be performed by a specialty-trained gynecologic oncologist in an appropriate referral center have been shown to have better outcomes( 5 - 7 ; 9 ; 37 ). Accordingly, a reliable tool to estimate the risk of invasive epithelial ovarian cancer in women with pelvic masses is necessary to triage women to the appropriate care provider before their surgical intervention. Many tools used currently utilize serum tumor markers. CA125 is the most commonly used serum biomarker for the evaluation of women with pelvic masses as 80% of women with EOC will have elevated serum levels. In fact, the sensitivity for elevated serum CA125 levels, when considered independently, for predicting EOC in women with a pelvic mass ranges from 43-81%( 15 ; 38 - 42 ). Unfortunately, the specificity of CA125 is limited by a number of factors. The CA125 glycoprotein is a coelomic epithelial antigen produced by the mesothelial cells that line the peritoneal, pleural and pericardial cavities. As such, serum concentrations of CA125 can be elevated by benign gynecologic and other medical conditions, such as normal menses, endometriosis, cirrhosis and congestive heart failure( 43 ; 44 ). In addition, mean levels of serum CA125 vary according to menopausal status, with higher values observed in premenopausal patients and a decreasing levels in postmenopausal women with increasing age( 40 ; 42 - 45 ). The limited sensitivity and specificity of CA125 alone has inspired the use of other modalities and novel tumor markers in combination with the test to improve the test’s ability to predict malignancy in women with pelvic masses. Human epididymis protein 4 (HE4) is made up of two whey acidic protein (WAP) domains and a 4 disulfide core and has been shown to be over-expressed by epithelial ovarian cancer tumors and circulate in the serum of patients with EOC( 46 ). HE4 is less likely to be elevated falsely in the setting of benign neoplasms as compared to serum CA125, and can be used to differentiate endometriomas from malignant ovarian tumors ( 39 ; 47 ). As individual tests, CA125 and HE4 have equivalent sensitivities for detecting malignancy in women with pelvic masses ( 48 ). However, there is a subset of ovarian cancers that do not express CA125 that do express HE4, suggesting that the tests in combination could be complementary ( 15 ; 49 ). In a prospective study evaluating the use of multiple serum tumor markers alone and in combination in the evaluation of women with pelvic masses, Moore et al reported a sensitivity of 72.9% for HE4 at a set specificity of 95%. Serum CA125 achieved a sensitivity of 43.3% at 95% specificity in this study. In combination, HE4 and CA125 achieved a sensitivity for detecting invasive epithelial ovarian cancer of 76.4% at a set specificity of 95%, higher than either test alone( 15 ). Even in combination serum biomarkers have limited sensitivities and specificities, so efforts to improve risk-stratification tools for women with pelvic masses have incorporated other factors from a woman’s clinical evaluation. One such tool is the Risk of Malignancy Index (RMI), which evaluates a woman’s risk for invasive disease by considering the woman’s menopausal status, ultrasound characteristics of her pelvic mass, and serum CA125 levels. The RMI was originally described in 1990 by Jacobs et al, and various versions of the calculations have been validated in several trials since. The reported sensitivity and specificity for the RMI in identifying epithelial ovarian cancer preoperatively ranges between 71-88.5% and 74.3-97% respectively( 12 ; 50 - 54 ). Ultrasound evaluation of pelvic masses can be limited by subjective interpretation of imaging studies, and another recently published algorithm for risk stratification of women with pelvic masses excludes them. The Predictive Probability Index (PP) considers a patient’s menopausal status along with serum CA125 and HE4 levels to determine the risk of malignancy in women with pelvic masses. In a prospective study evaluating 531 women with pelvic masses, the PP achieved a sensitivity of 88.7% for detecting invasive epithelial ovarian cancer and tumors of low malignant potential at a set specificity of 75%. When examining the ability to detect invasive epithelial ovarian cancer alone, the PP algorithm detect 94% of the invasive EOC in both pre and postmenopausal patients (89% premenopausal and 95% postmenopausal invasive EOC cases were detected) ( 55 ). The serum biomarkers HE4 and CA125 are limited in detecting epithelial ovarian cancers of the rare mucinous cell type( 15 ; 49 ; 55 ). Total inhibin is elevated in the serum of women with mucinous epithelial ovarian cancers( 56 ; 57 ). Another candidate serum tumor marker for mucinous tumors is CEA, which is used reliably in gastrointestinal tumors of mucinous histology. Immunohistochemical staining has demonstrated overexpression of CEA in a third of mucinous EOC tumors, and elevated serum levels have been documented in patients with mucinous epithelial ovarian cancer( 58 ; 59 ). Currently two biomarkers that are available for clinical use are CA125 and HE4. These two markers when used in combination complement each other for the prediction of ovarian cancer in women with a pelvic mass. HE4 has a greater specificity in the premenopausal age group due to its lack of over expression in patients with benign gynecologic diseases. CA125 and HE4 as a dual marker assay is a valuable tool for the risk assessment of a patient with an ovarian cyst or pelvic mass. The dual marker combination of HE4 and CA125 continues to be studied in a second large multicenter trial examining the predictive probability algorithms utility in a low risk population of patients presenting to general obstetrician and gynecologist.

CA125 has been extensively evaluated in attempts to develop screening models for EOC. Up to 80% of epithelial ovarian cancers express CA125 that is shed into serum that can be quantitatively measured ( 14 ). Fixed serum thresholds for CA125 (>35U/mL) have, however, limited utility as a screening tool as only 50-60% of women with stage I EOC will have elevated serum levels, thereby limiting its sensitivity for detecting ovarian cancer when it is still confined to the ovary ( 17 ). CA125 specificity is also compromised by the fact that many benign gynecologic and medical conditions, as well as other malignancies can result in elevated serum CA125 levels. Many of the gynecologic conditions are encountered less frequently in postmenopausal women and here the specificity of a single value of CA125 can approach 99%, but not 99.6%. The limitations of individual CA125 values and of transvaginal sonography for early detection of ovarian cancer have been highlighted by the Prostate, Lung, Colorectal and Ovarian (PLCO) screening trial. In this trial, 34,261 postmenopausal women were randomized to undergo CA125 and transvaginal sonography (TVS) screening annually for the first three years, followed by two more rounds of annual serum CA125 levels. Women were referred to a gynecologic surgeon if either the ultrasound or the CA125 was abnormal. The positive predictive value for CA125 alone was 3.7% and that for TVS 1%. If both were abnormal, the PPV was 23.5%, but 60% of invasive cancers would not have been detected if women had been referred for surgical consultation using this rule. Sensitivity for early stage disease was also a problem. Eighty-nine invasive ovarian or peritoneal cancers have been diagnosed, 60 of which were screen-detected. Of the 60 malignancies detected by the screening protocol, only 21% were stage I/II ( 18 ). Greater specificity and PPV can be attained by observing the trend of CA125 values over time. In 1992, Einhorn et al reported the specificity of a rising CA125 during annual screening for ovarian cancer in a small prospective trial with healthy women in Sweden. Serum samples were obtained from 5550 women, 175 were found to have elevated levels of CA125 (>35U/mL) and ultrasound was performed. Among those with elevated CA125, six were diagnosed with ovarian cancer, although only 2 were in stage I. Three women were subsequently diagnosed with EOC who had normal CA125 levels. This resulted in a specificity of 98.5% in women over the age of 50, but only 94.5% in women under the age of 50 years ( 19 ). While this study resulted in a suboptimal predictive value, the important observation was made that women who had elevated CA125 levels in the setting of an ovarian malignancy demonstrated progressive elevations over time, whereas, women with erroneously elevated “false positive” serum CA125 levels, had CA125 values that were stable or declined over time ( 19 ). More recently, Skates et al demonstrated in multiple serial samples from patients who eventually developed EOC had a change from their baseline serum CA125 levels up to two years prior to their clinical diagnosis of ovarian cancer. The phenomenon of a rising slope of serum CA125 levels as an early indicator for the development of an ovarian malignancy was used to develop the risk of ovarian cancer (ROC) algorithm, which takes into account a woman’s age and rate of rise or velocity of change in serum CA125 levels over time ( 16 ; 20 ; 21 ). With this algorithm, women with an elevated ROC risk assessment are referred for ultrasound evaluation. This approach increased the sensitivity of a single CA125 value of 62% to 86% in a retrospective study of 9233 women with 33,621 serum samples ( 16 ). The ROC was subsequently validated in a prospective study that reported specificity for the detection of invasive EOC of 99.8% with a positive predictive value of 19%, i.e., 5 operations per case of ovarian cancer detected( 21 ). The United Kingdom Collaborative Trial of Ovarian Cancer Screening (UKCTOCS) is evaluating the ROC algorithm prospectively in a study powered to detect a difference in survival. The UKCTOCS has enrolled over 200,000 postmenopausal women and randomized them to screening (100,000) versus no screening (100,000). The women assigned to the screening arm were further randomized to undergo annual TVS alone (50,000) or multimodality screening (MMS) with annual CA125 values interpreted by the ROC with referral of approximately 2% to TVS if the CA125 were rising (50,000). Of the 50,078 women who underwent MMS during their initial 2 years on study, 97 underwent surgery (0.2%). In the ultrasound screening (USS)group, 845 of 48,230 women underwent surgery (1.8%). For primary invasive cancers of the ovary and fallopian tube, the MMS approach achieved a sensitivity, specificity and positive predictive value of 89.5%, 99.8% and 35.1% respectively. The USS group reported sensitivity, specificity and positive-predictive value of 75%, 98.2% and 2.8%. Of note, 48% of the 58 invasive malignancies diagnosed were stage I/II( 22 ). Consequently, annual TVS required 36 operations per case of ovarian cancer detected, whereas the MMS with CA125 followed by TVS required only 2.8. It appears that the requirement for a rising CA125 precluded TVS detection of a great deal of benign disease which still requires surgery for a definitive diagnosis. Encouragingly, 48% of ovarian cancers were diagnosed in stage I or II in the prevalence phase of this trial, compared to the 25% of cases that one might expect. As the prevalence of the disease was twice its incidence, there may be as much as 2 years lead time, consistent with the practicality of annual screening. It still remains to be seen whether a stage shift will occur for incident cases during these next years and whether this will translate into a survival advantage. As treatment for early stage disease is not specified in the trial, it will be important to determine whether most participants had timely and appropriate chemotherapy in addition to surgery. Over the last 6 years, the Ovarian Specialized Program of Research Excellence (SPORE) at U.T. M.D. Anderson has been conducting a multi-site trial of screening for ovarian cancer in the United States for postmenopausal women at conventional risk using the ROC algorithm to refer approximately 2% of participants for TVS. If TVS has been positive, women are referred to surgery. Preliminary data from more than 9,500 annual CA125 assays in more than 3,000 women, suggest that the ROC will have a specificity of 99.2% for each encounter and 97.8% over several years of screening. TVS further increases the specificity. Nine women have been referred for surgery based on the ROC and TVS, with six ovarian cancers detected (3 borderline and 3 invasive) all in early stage, assuring a PPV of at least 30%, consistent with observations in the UKCTOCS (Lu, et al, unpublished data). As 20% of ovarian cancers express little or no CA125, many other serum tumor markers have been evaluated in combination with CA125 to improve the sensitivity, specificity and positive predictive value of the test ( 15 ; 23 ). A panel of six tumor markers, including CA-125, leptin, prolactin, osteopontin, insulin-like growth factor II and macrophage migration inhibitory factor was compared to CA125 alone in a study evaluating the serum of 362 healthy controls and 156 women with ovarian cancer. The ELISA-based panel improved the sensitivity and specificity of CA125 alone (72% and 95%) to 95.3% and 98.7%. The authors reported that 221 of 224 women in a test set that included 43 women with ovarian cancer were classified appropriately (98.7%)( 24 ). When the positive predictive value of this test was recalculated based on the prevalence of ovarian cancer in the general population, the result was 6.5%, as reported by Visintin et al which does not support using this test for screening of the general population. Data on two other “panel” tests have reported sensitivities and specificities ranging from 91-96% and 88-96% for ovarian cancer ( 25 ; 26 ). These panels have yet to be validated in prospective clinical trials. Another trial examining multiple markers looked at the various combinations of 9 markers including CA125, HE4, SMRP, CA72-4, Osteopontin, ERBB2, Inhibin, Activin and EGFR and demonstrated dual marker combination of CA125and HE4 had a greater sensitivity than either marker alone ( 15 ). Of some concern are the preliminary results from a collaborative trial from institutions that are funded by NCI SPORE grants in ovarian cancer. More than 50 biomarkers have been tested in the proximal serum samples taken from prior to diagnosis of ovarian cancer in the PLCO trial. In these preclinical samples, CA125 detected ovarian cancer in approximately 60% of patients within one year of diagnosis and little or no improvement was seen with multi-marker panels( 27 ). Novel approaches will be required to detect pre-clinical disease. Urinary markers have been evaluated for the early detection of EOC. At least in theory, small amounts of low molecular weight biomarkers (<50 kD) could pass through the glomerulus and be detected in urine before serum levels become elevated. Urine mesothelin (SMRP) exhibited greater sensitivity for early stage ovarian cancer than did hCG free beta subunit or beta subunit core fragment ( 28 ). The anti-apoptotic protein Bcl-2 has also been found elevated in urine from ovarian cancer patients( 29 ) and complementarity has been detected between the two biomarkers (unpublished data). Novel urinary analytes deserve further attention as targets for screening. Autoantibodies provide another approach to detecting preclinical disease with greater sensitivity. Small volumes of ovarian cancer could evoke a humoral immune response, breaking tolerance by the presentation of mutant, overexpressed or mal distributed tumor associated proteins ( 30 ). More than 60 different human protein target antigens have been reported in the literature over the last two decades. Recent studies have utilized protein arrays with 5,000-8,000 human proteins expressed in insect cells ( 31 ; 32 ). Availability of arrays constructed from human proteins expressed in human cells may provide even more faithful representation of antigenic epitopes recognized by human autoantibodies. Substantial attention has been given to autoantibodies reactive with wild-type TP53 ( 33 ) that arise in patients with high grade, often late stage serous ovarian carcinomas with p53 mutations( 34 ). Overall, approximately 20% of patients will have autoantibodies against the wild type TP53, although antibodies have generally not been measured against mutant protein or in pre-clinical samples. Autoantibodies might detect at least a fraction of patients with “type 2” high grade ovarian cancers, before metastasis occurs, complementing CA125 and other more traditional biomarkers, if autoantibodies prove sufficiently specific. The use of biomarkers as part of screening protocols is clearly an important area of research in ovarian cancer. Final results of the UKCTOCS trial with CA125 followed by TVS will be important, but multiple markers are likely to be required to detect most early stage disease at the time of conventional diagnosis. In addition to panels of serum biomarkers, both urinary analytes and serum autoantibodies deserve more detailed attention.

The only two serum biomarkers currently clinically available and approved by the FDA for monitoring patients with EOC are CA125 and HE4. Approximately 90% of patients with EOC have tumors that overexpress either CA125 or HE4, and the changes in a patients serum levels accurately reflect regression or progression of disease( 60 - 63 ). Reliable tumor markers can be used to monitor response to treatment provided the biomarker serum levels are elevated at the time of diagnosis. The most commonly used biomarker for monitoring treatment of EOC is CA125, as changes in serum levels have been demonstrated to correspond to progression or regression of disease( 60 ; 61 ; 64 ). CA125 can be expressed not only by ovarian cancers, but also by inflamed peritoneum. Consequently approximately 90% of advanced ovarian cancer can be monitored with CA125, but some 10% of ovarian cancer patients will not have elevated serum CA125 levels and are therefore left without a reliable marker for monitoring of disease. There is a substantial correlation between HE4 and CA125 for monitoring the biologic activity of epithelial ovarian cancer( 65 ). Recently, the novel serum biomarker HE4 has been shown to be elevated in over half of the EOC where CA125 was not a marker resulting in over 90% of all EOC having at least CA125 or HE4 as a biomarker for monitoring disease status( 62 ; 63 ). CA125 is the most well studied serum biomarker for monitoring EOC and a 50% decrease in serum CA125 levels has been shown to correlate with disease response as measured by conventional criteria in phase II clinical trials ( 64 ). Equally, a doubling of CA125 from baseline has been shown to be consistent with failure of a drug and progressive disease. Because a rise in serum biomarkers can indicate recurrence or progression of disease, evaluating serum markers as part of cancer surveillance has become a clinical standard. In patients whose CA125 is initially elevated and normalizes after treatment, the Gynecologic Cancer Intergroup (GCIG) defines progression based on two CA125 levels, one week apart, that are each at least twice the upper limit of normal for the specific assay being used. In patients with serum CA125 levels that never normalized, progression is defined as two values that are at least twice the patients’ CA125 nadir. In a study evaluating 255 patients with elevated CA125 levels undergoing treatment for EOC, Rustin et al reported that a doubling of a patient’s post-treatment nadir or values twice that of the upper limit of normal predicted recurrent EOC with a sensitivity of 86%, specificity of 91%, PPV 95% and NPV 78%( 66 ). The only other tumor marker approved by the United States FDA and clinically available for monitoring patients with EOC for recurrence or progression is HE4. In a study evaluating serum HE4 levels of women with EOC, serial HE4 levels from 80 patients either undergoing treatment for EOC or being monitored for recurrence showed that changes in HE4 values were not inferior to changes in CA125 values in accordance with clinical status. CA125 correlated with clinical status in 78.8% (63/80) and HE4 correlated in 76.2% (61/80). In consideration of all cases either CA125 or HE4 correlated with clinical status for 83.8% (67/80)of patients( 65 ). Serial measurements of serum biomarkers are helpful for detecting early recurrence of disease, and serum elevations may precede clinical or radiological detectable disease by a median time of 2 to 6 months ( 67 ; 68 ). However, benefit of the early detection of recurrent disease based on serologic recurrence has recently come under question. At the 2009 American Society of Clinical Oncologists, Rustin, et al, presented a trial conducted over the last decade in the United Kingdom and several centers in Europe comparing the impact on ovarian cancer survival of a physician’s knowing or not knowing that CA125 was rising in the setting of disease recurrence. No survival advantage was found for patients treated for recurrent disease based on a rising CA125 when compared to patients treated on the basis of subsequent symptoms and signs( 69 ) . CA125 accurately predicted disease recurrence, but three months of lead time did not appear to impact on survival based upon the treatment given. Each participating physician was, however free to choose how patients were treated. Only one third of the patients received a combination of a taxane and platinum compounds in either arm. As carboplatin and paclitaxel have been shown to provide superior survival over carboplatin alone in recurrent disease( 70 ), it appears that two thirds of patients received suboptimal therapy by today’s standards. With only three months lead time, suboptimal chemotherapy would have minimized any advantage to early treatment. In addition, patients were not stratified based on the extent of primary cytoreduction nor were they staged with CT scans at the completion of chemotherapy, so that balance of the two treatment arms was not certain. Thus, the value of detecting recurrent EOC before it is clinically evident needs further evaluation. This study certainly does point to the importance of improving therapy for recurrent disease. As many patients have only a year of life after recurrence, earlier detection of disease would provide a greater opportunity to participate in clinical trials or to utilize the several conventional agents currently available for treatment. As newer classes of drugs and biological agents become available there may be an advantage to treating patients with low volume disease.